GlassScriptPhysician profile
Adam D Isbell
NPI 1518196070
$10,026.73
in general payments reported to CMS, 2019-2025
42 companies · $918 in 2025
The $918 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $1,785 · 2021: $2,248 · 2022: $1,278 · 2023: $1,086 · 2024: $923 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,033.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,138.44 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $808.10 | 2021-2025 | |
| Lilly USA, LLC | $719.33 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $582.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $414.21 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $340.31 | 2019-2022 | |
| Amarin Pharma, INC. | $334.99 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.52 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $277.37 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.85 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $209.36 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $200.86 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $142.33 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Teva Pharmaceuticals USA, INC. | $102.79 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Isbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.